CN115607510A - High-concentration oleanolic acid nanoemulsion composition and preparation method thereof - Google Patents
High-concentration oleanolic acid nanoemulsion composition and preparation method thereof Download PDFInfo
- Publication number
- CN115607510A CN115607510A CN202110419745.1A CN202110419745A CN115607510A CN 115607510 A CN115607510 A CN 115607510A CN 202110419745 A CN202110419745 A CN 202110419745A CN 115607510 A CN115607510 A CN 115607510A
- Authority
- CN
- China
- Prior art keywords
- extract
- essential oil
- oleanolic acid
- hair
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 title claims abstract description 179
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 title claims abstract description 179
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 title claims abstract description 179
- 229940100243 oleanolic acid Drugs 0.000 title claims abstract description 179
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 title claims abstract description 179
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 title claims abstract description 178
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 116
- 239000000203 mixture Substances 0.000 title claims abstract description 97
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- 239000000341 volatile oil Substances 0.000 claims abstract description 186
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 70
- 239000000839 emulsion Substances 0.000 claims abstract description 38
- 150000003505 terpenes Chemical class 0.000 claims abstract description 34
- 235000007586 terpenes Nutrition 0.000 claims abstract description 33
- 210000004209 hair Anatomy 0.000 claims abstract description 32
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims abstract description 30
- 238000003756 stirring Methods 0.000 claims abstract description 30
- 239000002537 cosmetic Substances 0.000 claims abstract description 28
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960003321 baicalin Drugs 0.000 claims abstract description 25
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 25
- 239000004094 surface-active agent Substances 0.000 claims abstract description 25
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 claims abstract description 23
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 claims abstract description 23
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 claims abstract description 23
- 235000011576 oleuropein Nutrition 0.000 claims abstract description 23
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 claims abstract description 23
- 239000000654 additive Substances 0.000 claims abstract description 19
- 238000002156 mixing Methods 0.000 claims abstract description 19
- 239000004064 cosurfactant Substances 0.000 claims abstract description 15
- 230000001804 emulsifying effect Effects 0.000 claims abstract description 12
- 230000000996 additive effect Effects 0.000 claims abstract description 8
- 238000010008 shearing Methods 0.000 claims abstract description 3
- 239000000284 extract Substances 0.000 claims description 70
- -1 polyoxyethylene Polymers 0.000 claims description 41
- 238000004945 emulsification Methods 0.000 claims description 31
- 201000004384 Alopecia Diseases 0.000 claims description 30
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims description 25
- 239000010642 eucalyptus oil Substances 0.000 claims description 25
- 229940044949 eucalyptus oil Drugs 0.000 claims description 25
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 23
- 230000003779 hair growth Effects 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000000499 gel Substances 0.000 claims description 22
- 244000165082 Lavanda vera Species 0.000 claims description 20
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 20
- 239000001102 lavandula vera Substances 0.000 claims description 20
- 235000018219 lavender Nutrition 0.000 claims description 20
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 19
- 150000004676 glycans Chemical class 0.000 claims description 19
- 229920001282 polysaccharide Polymers 0.000 claims description 19
- 239000005017 polysaccharide Substances 0.000 claims description 19
- 241000218645 Cedrus Species 0.000 claims description 18
- 239000004359 castor oil Substances 0.000 claims description 18
- 235000019438 castor oil Nutrition 0.000 claims description 18
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 18
- 241001061264 Astragalus Species 0.000 claims description 17
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 17
- 235000006533 astragalus Nutrition 0.000 claims description 17
- 239000012153 distilled water Substances 0.000 claims description 17
- 210000004233 talus Anatomy 0.000 claims description 17
- 239000003921 oil Substances 0.000 claims description 16
- 231100000360 alopecia Toxicity 0.000 claims description 15
- 229960003632 minoxidil Drugs 0.000 claims description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims description 14
- 240000003553 Leptospermum scoparium Species 0.000 claims description 14
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 14
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 13
- 206010000496 acne Diseases 0.000 claims description 13
- 238000004090 dissolution Methods 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- 244000246386 Mentha pulegium Species 0.000 claims description 12
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 12
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 235000001050 hortel pimenta Nutrition 0.000 claims description 12
- 239000003755 preservative agent Substances 0.000 claims description 12
- 239000002562 thickening agent Substances 0.000 claims description 12
- 239000006210 lotion Substances 0.000 claims description 11
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 10
- 125000005456 glyceride group Chemical group 0.000 claims description 10
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 10
- 206010068168 androgenetic alopecia Diseases 0.000 claims description 9
- 201000002996 androgenic alopecia Diseases 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 9
- 230000002335 preservative effect Effects 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 8
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 235000006708 antioxidants Nutrition 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 8
- 235000019441 ethanol Nutrition 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 239000003906 humectant Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000004530 micro-emulsion Substances 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 8
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 7
- 102000008186 Collagen Human genes 0.000 claims description 7
- 108010035532 Collagen Proteins 0.000 claims description 7
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 7
- 229920002125 Sokalan® Polymers 0.000 claims description 7
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 7
- 235000011399 aloe vera Nutrition 0.000 claims description 7
- 239000000051 antiandrogen Substances 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- 229920001436 collagen Polymers 0.000 claims description 7
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- 229960004039 finasteride Drugs 0.000 claims description 7
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 claims description 7
- 229960005150 glycerol Drugs 0.000 claims description 7
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 7
- 239000002453 shampoo Substances 0.000 claims description 7
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 7
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 7
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000000265 homogenisation Methods 0.000 claims description 6
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000865 liniment Substances 0.000 claims description 6
- 229940040145 liniment Drugs 0.000 claims description 6
- 229960005323 phenoxyethanol Drugs 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 239000003974 emollient agent Substances 0.000 claims description 5
- 235000015097 nutrients Nutrition 0.000 claims description 5
- 239000000419 plant extract Substances 0.000 claims description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 5
- 241001116389 Aloe Species 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 4
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 claims description 4
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 4
- 240000007817 Olea europaea Species 0.000 claims description 4
- 235000002725 Olea europaea Nutrition 0.000 claims description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 claims description 4
- 229940015301 baicalein Drugs 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 4
- SVURIXNDRWRAFU-OGMFBOKVSA-N cedrol Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@@H]1[C@@](O)(C)CC2 SVURIXNDRWRAFU-OGMFBOKVSA-N 0.000 claims description 4
- 229940026455 cedrol Drugs 0.000 claims description 4
- PCROEXHGMUJCDB-UHFFFAOYSA-N cedrol Natural products CC1CCC2C(C)(C)C3CC(C)(O)CC12C3 PCROEXHGMUJCDB-UHFFFAOYSA-N 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 235000006539 genistein Nutrition 0.000 claims description 4
- 229940045109 genistein Drugs 0.000 claims description 4
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 4
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 4
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 4
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 claims description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims description 4
- SVURIXNDRWRAFU-UHFFFAOYSA-N juniperanol Natural products C1C23C(C)CCC3C(C)(C)C1C(O)(C)CC2 SVURIXNDRWRAFU-UHFFFAOYSA-N 0.000 claims description 4
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims description 4
- 229940083980 lavender extract Drugs 0.000 claims description 4
- 235000020723 lavender extract Nutrition 0.000 claims description 4
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 4
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 229940114496 olive leaf extract Drugs 0.000 claims description 4
- 239000003002 pH adjusting agent Substances 0.000 claims description 4
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 4
- 230000009759 skin aging Effects 0.000 claims description 4
- 229940032094 squalane Drugs 0.000 claims description 4
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 3
- 244000144927 Aloe barbadensis Species 0.000 claims description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Natural products CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 3
- 208000003024 Diffuse alopecia Diseases 0.000 claims description 3
- 206010016936 Folliculitis Diseases 0.000 claims description 3
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- 239000010404 Scutellaria baicalensis extract Substances 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 208000004631 alopecia areata Diseases 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 230000002280 anti-androgenic effect Effects 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 229940030275 epigallocatechin gallate Drugs 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 229940089161 ginsenoside Drugs 0.000 claims description 3
- 229930182494 ginsenoside Natural products 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 229930003658 monoterpene Natural products 0.000 claims description 3
- 150000002773 monoterpene derivatives Chemical class 0.000 claims description 3
- 235000002577 monoterpenes Nutrition 0.000 claims description 3
- 239000002304 perfume Substances 0.000 claims description 3
- 235000011007 phosphoric acid Nutrition 0.000 claims description 3
- 229960000502 poloxamer Drugs 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 235000020748 rosemary extract Nutrition 0.000 claims description 3
- 229940092258 rosemary extract Drugs 0.000 claims description 3
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 claims description 3
- 229930004725 sesquiterpene Natural products 0.000 claims description 3
- 150000004354 sesquiterpene derivatives Chemical class 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 201000001297 telogen effluvium Diseases 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims description 2
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 claims description 2
- BFZHCUBIASXHPK-QJSKAATBSA-N 11alpha-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)C[C@H]2O BFZHCUBIASXHPK-QJSKAATBSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 2
- PBBGSZCBWVPOOL-HDICACEKSA-N 4-[(1r,2s)-1-ethyl-2-(4-hydroxyphenyl)butyl]phenol Chemical compound C1([C@H](CC)[C@H](CC)C=2C=CC(O)=CC=2)=CC=C(O)C=C1 PBBGSZCBWVPOOL-HDICACEKSA-N 0.000 claims description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical class NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 2
- 241000195940 Bryophyta Species 0.000 claims description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 2
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- 240000000774 Cunila origanoides Species 0.000 claims description 2
- 235000018274 Cunila origanoides Nutrition 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims description 2
- 235000014866 Dictamnus albus Nutrition 0.000 claims description 2
- RPWFJAMTCNSJKK-UHFFFAOYSA-N Dodecyl gallate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 RPWFJAMTCNSJKK-UHFFFAOYSA-N 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 244000119298 Emblica officinalis Species 0.000 claims description 2
- 235000015489 Emblica officinalis Nutrition 0.000 claims description 2
- 239000010282 Emodin Substances 0.000 claims description 2
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 claims description 2
- VAPSMQAHNAZRKC-PQWRYPMOSA-N Epristeride Chemical compound C1C=C2C=C(C(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC2 VAPSMQAHNAZRKC-PQWRYPMOSA-N 0.000 claims description 2
- 241000628997 Flos Species 0.000 claims description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 2
- 240000008397 Ganoderma lucidum Species 0.000 claims description 2
- 241001071795 Gentiana Species 0.000 claims description 2
- 241000208680 Hamamelis mollis Species 0.000 claims description 2
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 claims description 2
- 229920002971 Heparan sulfate Polymers 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 239000009636 Huang Qi Substances 0.000 claims description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 2
- 229920000288 Keratan sulfate Polymers 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- 239000004166 Lanolin Substances 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 claims description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 claims description 2
- 241000180649 Panax notoginseng Species 0.000 claims description 2
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
- 229920000148 Polycarbophil calcium Polymers 0.000 claims description 2
- 229920000289 Polyquaternium Polymers 0.000 claims description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 2
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 claims description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 2
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 2
- 241000207929 Scutellaria Species 0.000 claims description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 2
- 241000246044 Sophora flavescens Species 0.000 claims description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 2
- 241001300193 Speranskia Species 0.000 claims description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims description 2
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 244000274883 Urtica dioica Species 0.000 claims description 2
- 235000009108 Urtica dioica Nutrition 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229930003451 Vitamin B1 Natural products 0.000 claims description 2
- 229930003471 Vitamin B2 Natural products 0.000 claims description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 2
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 2
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 claims description 2
- 239000002250 absorbent Substances 0.000 claims description 2
- 230000002745 absorbent Effects 0.000 claims description 2
- 229960005305 adenosine Drugs 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- 229960000458 allantoin Drugs 0.000 claims description 2
- 239000009188 angelicae sinensis extract Substances 0.000 claims description 2
- 230000003712 anti-aging effect Effects 0.000 claims description 2
- 229960000271 arbutin Drugs 0.000 claims description 2
- 229960003121 arginine Drugs 0.000 claims description 2
- 229960002255 azelaic acid Drugs 0.000 claims description 2
- 229960002233 benzalkonium bromide Drugs 0.000 claims description 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 2
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 150000008366 benzophenones Chemical class 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
- 229960000997 bicalutamide Drugs 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 229940067596 butylparaben Drugs 0.000 claims description 2
- 229960001948 caffeine Drugs 0.000 claims description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 2
- 229940119217 chamomile extract Drugs 0.000 claims description 2
- 235000020221 chamomile extract Nutrition 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 2
- 229960001380 cimetidine Drugs 0.000 claims description 2
- 150000001851 cinnamic acid derivatives Chemical class 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 229960005188 collagen Drugs 0.000 claims description 2
- 235000012754 curcumin Nutrition 0.000 claims description 2
- 229940109262 curcumin Drugs 0.000 claims description 2
- 239000004148 curcumin Substances 0.000 claims description 2
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 claims description 2
- 229960003843 cyproterone Drugs 0.000 claims description 2
- 229960003067 cystine Drugs 0.000 claims description 2
- 229960002887 deanol Drugs 0.000 claims description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 2
- 229940008099 dimethicone Drugs 0.000 claims description 2
- 229930004069 diterpene Natural products 0.000 claims description 2
- 235000010386 dodecyl gallate Nutrition 0.000 claims description 2
- 229960004199 dutasteride Drugs 0.000 claims description 2
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 claims description 2
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 claims description 2
- 229950009537 epristeride Drugs 0.000 claims description 2
- 235000019126 equol Nutrition 0.000 claims description 2
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 claims description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 2
- 230000001815 facial effect Effects 0.000 claims description 2
- 235000001785 ferulic acid Nutrition 0.000 claims description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 2
- 229940114124 ferulic acid Drugs 0.000 claims description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 2
- 229960002074 flutamide Drugs 0.000 claims description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 2
- 235000008434 ginseng Nutrition 0.000 claims description 2
- 229930182478 glucoside Natural products 0.000 claims description 2
- 229940100242 glycol stearate Drugs 0.000 claims description 2
- 229940094952 green tea extract Drugs 0.000 claims description 2
- 235000020688 green tea extract Nutrition 0.000 claims description 2
- 229920000591 gum Polymers 0.000 claims description 2
- 239000000118 hair dye Substances 0.000 claims description 2
- 239000008266 hair spray Substances 0.000 claims description 2
- OIKBVOIOVNEVJR-UHFFFAOYSA-N hexadecyl 6-methylheptanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC(C)C OIKBVOIOVNEVJR-UHFFFAOYSA-N 0.000 claims description 2
- 229950001996 hexestrol Drugs 0.000 claims description 2
- WTDHMFBJQJSTMH-UHFFFAOYSA-N hinokiflavone Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C(OC=3C=CC(=CC=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)=C(O)C=C2O1 WTDHMFBJQJSTMH-UHFFFAOYSA-N 0.000 claims description 2
- HLFVFEBKCLAGBY-UHFFFAOYSA-N hinokiflavone Natural products Oc1ccc(cc1)C2=COc3cc(O)c(Oc4ccc(cc4)C5=CC(=O)c6c(O)cc(O)cc6O5)c(O)c3C2=O HLFVFEBKCLAGBY-UHFFFAOYSA-N 0.000 claims description 2
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940093629 isopropyl isostearate Drugs 0.000 claims description 2
- 235000008777 kaempferol Nutrition 0.000 claims description 2
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims description 2
- 229940039717 lanolin Drugs 0.000 claims description 2
- 235000019388 lanolin Nutrition 0.000 claims description 2
- 229960004400 levonorgestrel Drugs 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims description 2
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims description 2
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000009498 luteolin Nutrition 0.000 claims description 2
- 229960003646 lysine Drugs 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims description 2
- 235000011929 mousse Nutrition 0.000 claims description 2
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 claims description 2
- 229940116852 myricetin Drugs 0.000 claims description 2
- 235000007743 myricetin Nutrition 0.000 claims description 2
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- 229940053934 norethindrone Drugs 0.000 claims description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 2
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 claims description 2
- 229960001679 octinoxate Drugs 0.000 claims description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims description 2
- SWUARLUWKZWEBQ-VQHVLOKHSA-N phenethyl caffeate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-VQHVLOKHSA-N 0.000 claims description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 2
- SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 claims description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 claims description 2
- 229950005134 polycarbophil Drugs 0.000 claims description 2
- 229920000223 polyglycerol Polymers 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 2
- 235000013824 polyphenols Nutrition 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 claims description 2
- 239000000473 propyl gallate Substances 0.000 claims description 2
- 235000010388 propyl gallate Nutrition 0.000 claims description 2
- 229940075579 propyl gallate Drugs 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 229940064064 purslane extract Drugs 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000005875 quercetin Nutrition 0.000 claims description 2
- 229960001285 quercetin Drugs 0.000 claims description 2
- 150000003244 quercetin derivatives Chemical class 0.000 claims description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 2
- 235000005493 rutin Nutrition 0.000 claims description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 2
- 229960004555 rutoside Drugs 0.000 claims description 2
- 229930194301 safflor yellow Natural products 0.000 claims description 2
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 claims description 2
- 150000003872 salicylic acid derivatives Chemical class 0.000 claims description 2
- 239000010018 saw palmetto extract Substances 0.000 claims description 2
- 229940063845 saw palmetto extract Drugs 0.000 claims description 2
- 229940057910 shea butter Drugs 0.000 claims description 2
- 229940001607 sodium bisulfite Drugs 0.000 claims description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 2
- 239000001540 sodium lactate Substances 0.000 claims description 2
- 229940005581 sodium lactate Drugs 0.000 claims description 2
- 235000011088 sodium lactate Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 2
- 229960002256 spironolactone Drugs 0.000 claims description 2
- 235000021286 stilbenes Nutrition 0.000 claims description 2
- 235000013616 tea Nutrition 0.000 claims description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 2
- 229940042585 tocopherol acetate Drugs 0.000 claims description 2
- 230000001256 tonic effect Effects 0.000 claims description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 2
- 239000008513 turmeric extract Substances 0.000 claims description 2
- 229940052016 turmeric extract Drugs 0.000 claims description 2
- 235000020240 turmeric extract Nutrition 0.000 claims description 2
- 229940099259 vaseline Drugs 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000010374 vitamin B1 Nutrition 0.000 claims description 2
- 239000011691 vitamin B1 Substances 0.000 claims description 2
- 235000019164 vitamin B2 Nutrition 0.000 claims description 2
- 239000011716 vitamin B2 Substances 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 150000003700 vitamin C derivatives Chemical class 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 229940118846 witch hazel Drugs 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims 1
- 240000004371 Panax ginseng Species 0.000 claims 1
- 235000010575 Pueraria lobata Nutrition 0.000 claims 1
- 244000046146 Pueraria lobata Species 0.000 claims 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims 1
- 150000004141 diterpene derivatives Chemical class 0.000 claims 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 claims 1
- 230000001333 moisturizer Effects 0.000 claims 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical group CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 1
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 claims 1
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 claims 1
- 235000003687 soy isoflavones Nutrition 0.000 claims 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 claims 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 14
- 208000017520 skin disease Diseases 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 35
- 230000000694 effects Effects 0.000 description 28
- 239000000047 product Substances 0.000 description 21
- 239000012071 phase Substances 0.000 description 20
- 230000001737 promoting effect Effects 0.000 description 16
- 239000010677 tea tree oil Substances 0.000 description 16
- 229940111630 tea tree oil Drugs 0.000 description 16
- 229940060184 oil ingredients Drugs 0.000 description 15
- 210000003780 hair follicle Anatomy 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- 235000006679 Mentha X verticillata Nutrition 0.000 description 12
- 235000002899 Mentha suaveolens Nutrition 0.000 description 12
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 230000008569 process Effects 0.000 description 10
- 238000005303 weighing Methods 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 102000001307 androgen receptors Human genes 0.000 description 8
- 108010080146 androgen receptors Proteins 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 229940113120 dipropylene glycol Drugs 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 201000004624 Dermatitis Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 230000010494 opalescence Effects 0.000 description 5
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 4
- WRYLYDPHFGVWKC-SNVBAGLBSA-N 4-Terpineol Natural products CC(C)[C@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-SNVBAGLBSA-N 0.000 description 4
- 235000005979 Citrus limon Nutrition 0.000 description 4
- 244000131522 Citrus pyriformis Species 0.000 description 4
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 4
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102000014429 Insulin-like growth factor Human genes 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229960005233 cineole Drugs 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000024963 hair loss Diseases 0.000 description 4
- 230000003676 hair loss Effects 0.000 description 4
- 230000003660 hair regeneration Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 125000000955 oleanolic acid group Chemical group 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229960001712 testosterone propionate Drugs 0.000 description 4
- 238000009210 therapy by ultrasound Methods 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 3
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 3
- 244000004281 Eucalyptus maculata Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- RBNWAMSGVWEHFP-UHFFFAOYSA-N cis-p-Menthan-1,8-diol Natural products CC(C)(O)C1CCC(C)(O)CC1 RBNWAMSGVWEHFP-UHFFFAOYSA-N 0.000 description 3
- 238000005260 corrosion Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229930007744 linalool Natural products 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 238000011587 new zealand white rabbit Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000003381 solubilizing effect Effects 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 2
- 102000015735 Beta-catenin Human genes 0.000 description 2
- 240000007436 Cananga odorata Species 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 240000004784 Cymbopogon citratus Species 0.000 description 2
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 2
- 244000166675 Cymbopogon nardus Species 0.000 description 2
- 235000018791 Cymbopogon nardus Nutrition 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 240000006927 Foeniculum vulgare Species 0.000 description 2
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 2
- 239000005792 Geraniol Substances 0.000 description 2
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 2
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 240000002924 Platycladus orientalis Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 235000007303 Thymus vulgaris Nutrition 0.000 description 2
- 240000002657 Thymus vulgaris Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 2
- 229940043234 carbomer-940 Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- MMKRHZKQPFCLLS-UHFFFAOYSA-N ethyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OCC MMKRHZKQPFCLLS-UHFFFAOYSA-N 0.000 description 2
- 229940113087 geraniol Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000003049 inorganic solvent Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000002539 nanocarrier Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000037368 penetrate the skin Effects 0.000 description 2
- 150000002966 pentacyclic triterpenoids Chemical class 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 239000001585 thymus vulgaris Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- KIUKXJAPPMFGSW-YXBJCWEESA-N (2s,4s,5r,6s)-6-[(2s,3r,5s,6r)-3-acetamido-2-[(3s,4r,5r,6r)-6-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@@H]3[C@@H]([C@@H](O)C(O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)C(C(O)=O)O1 KIUKXJAPPMFGSW-YXBJCWEESA-N 0.000 description 1
- GXWUEMSASMVWKO-GNLHUFSQSA-N (4as,6ar,6as,6br,10s,12ar,14br)-10-[(2s,3r,4s,5s)-4,5-dihydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)CO[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CCC2C1(C)C)C)(C)CC[C@]1(CCC(C[C@@H]14)(C)C)C(O)=O)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GXWUEMSASMVWKO-GNLHUFSQSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 235000007571 Cananga odorata Nutrition 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000208152 Geranium Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 240000006982 Guaiacum sanctum Species 0.000 description 1
- 235000004440 Guaiacum sanctum Nutrition 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- 240000005183 Lantana involucrata Species 0.000 description 1
- ACFGRWJEQJVZTM-LEJBHHMKSA-L Magnesium L-ascorbic acid-2-phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O ACFGRWJEQJVZTM-LEJBHHMKSA-L 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000011751 Pogostemon cablin Nutrition 0.000 description 1
- 240000002505 Pogostemon cablin Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 206010074268 Reproductive toxicity Diseases 0.000 description 1
- 235000002911 Salvia sclarea Nutrition 0.000 description 1
- 244000182022 Salvia sclarea Species 0.000 description 1
- 240000000513 Santalum album Species 0.000 description 1
- 235000008632 Santalum album Nutrition 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- WWVKQTNONPWVEL-UHFFFAOYSA-N caffeic acid phenethyl ester Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCC1=CC=CC=C1 WWVKQTNONPWVEL-UHFFFAOYSA-N 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000010627 cedar oil Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005536 corrosion prevention Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000001224 daucus carota l. seed absolute Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000003721 exogen phase Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical group CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 230000036618 natural shedding Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 150000002887 oleanolic acids Chemical class 0.000 description 1
- 239000008601 oleoresin Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000010664 perilla essential oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 230000007696 reproductive toxicity Effects 0.000 description 1
- 231100000372 reproductive toxicity Toxicity 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940107889 rogaine Drugs 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 229940119485 safflower extract Drugs 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 231100000130 skin irritation / corrosion testing Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/068—Microemulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/49—Solubiliser, Solubilising system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
A high-concentration oleanolic acid nanoemulsion composition and a preparation method thereof belong to the technical field of medicines and cosmetics. The oleanolic acid nanoemulsion composition comprises 0.01-8% of oleanolic acid; 1 to 40 percent of surfactant; 1% -40% of cosurfactant; 0.2 to 20 percent of essential oil containing terpene; 0 to 2 percent of baicalin; 0 to 5 percent of oleuropein; a proper amount of additive; the balance being water. Adding cosurfactant and essential oil containing terpene into a container A, and mixing and stirring uniformly; adding a surfactant and mixing uniformly; then adding oleanolic acid and other active ingredients, and stirring until the oleanolic acid and the other active ingredients are completely dissolved; adding water and additives into the container B to obtain a water phase; slowly adding the mixture in the container A into the water phase in the container B while stirring to obtain primary emulsion; shearing and emulsifying at high speed, and fully emulsifying for the second time. Can be used in preparing cosmetics, medicines for treating skin diseases, and skin and hair care products.
Description
Technical Field
The invention belongs to the technical field of medicines and cosmetics, and particularly relates to a high-concentration oleanolic acid nanoemulsion composition and a preparation method thereof.
Background
Oleanolic acid (Oleanolic acid), also known as terraangelic acid, is a natural pentacyclic triterpenoid, widely exists in plants, and exists in various plants as free bodies and glycoside bodies. Generally, the content is 0.2-2%. The powder obtained after the oleanolic acid purification is white crystal, odorless and tasteless. Is unstable to acid and alkali. Melting point 308-310 deg.C, [ alpha ]20D +73.3 deg. (c =0.15, chloroform), and is insoluble in water.
Oleanolic acid has wide pharmacological actions, such as antibacterial, antiinflammatory, antioxidant, antitumor, liver protecting, antidiabetic, hair growth promoting, wound healing promoting, scar formation resisting, collagen formation promoting, and antiallergic effects. At present, oleanolic acid is clinically used for the auxiliary treatment of acute and chronic hepatitis, and is safe and has no toxic or side effect. The development and utilization of oleanolic acid except liver protection are rare, and the clinical preparations of the oleanolic acid mainly comprise two types, namely tablets and capsules.
It is worth noting that some herbal plants rich in oleanolic acid, such as the traditional Chinese medicine fructus ligustri lucidi, are traditionally used in china for the purpose of treating alopecia, promoting hair regeneration and blacking hair; it has been demonstrated that oleanolic acid can upregulate the Wnt/β -Catenin signaling pathway to promote hair growth and extend the anagen phase of hair follicles in vitro (Liu B, et al, β -Catenin is secreted in oleanolic acid-dependent promotion of promotion in human hair matrix cells in an in vitro organic culture model [ J ]. Fitolerapia, 2017, 121; oleanolic acid has been shown to promote the proliferation of human hair follicle stem cells cultured in vitro (Liuben, old swallow, easy atlantoan, etc.; oleanolic acid's influence on the proliferation of human hair follicle stem cells cultured in vitro [ J ]. J. Dermatology, 2017,24 (2): 68-71.); oleanolic ACID has been shown to down-regulate GENE EXPRESSION OF 5A REDUCTASE AND androgen receptor IN hair follicles cultured IN VITRO AND to up-regulate the EXPRESSION levels OF insulin-like growth factor (IGF-1), vascular Endothelial Growth Factor (VEGF) (Cao C, liu Y, et al, EFFECT OF OLEANOLIC ACID ON 5A-REDUCTASE ACTIVITY, DPCS PROLIFERATION AND GENE EXPRESSION CORRELATED WITH DROGENIC ALOPECEIA IN VITRO [ J ]. ACTA MEDIERA, 2019,35 (4): 2159-2165); these studies indicate that oleanolic acid has broad application prospects as a product for promoting hair growth and reducing hair loss.
Oleanolic acid has good supplement or substitute effect on existing hair growth or alopecia treatment; the united states Food and Drug Administration (FDA) has approved only two drugs for the treatment of male androgenetic alopecia (AGA): topical minoxidil (minoxidil) and oral finasteride (finasteride); finasteride is an inhibitor of type 2 alpha-reductase, which prevents DHT-induced hair follicle miniaturization by inhibiting the conversion of testosterone hormone (T) to Dihydrotestosterone (DHT), resulting in a decrease in DHT formation; for AGA patients, finasteride is generally more effective than minoxidil; however, finasteride has the potential risk of causing male sexual side effects and causing anxiety, depression; minoxidil is a nonspecific hair growth promoting drug, the mechanism of promoting hair growth is not completely clear, minoxidil is a potassium channel opener, and more blood and nutrients can enter hair follicles by expanding blood vessels, so that hair growth is promoted; the common adverse effects of minoxidil are mild dermatitis, itching, redness or irritation of the scalp and hirsutism, even leading to an exacerbation of hair loss, "Rogaine" manufacturers indicate that minoxidil causes hair loss as a common side effect and describe the process as "shedding phase"; and the minoxidil is easy to be removed to the level before the minoxidil is used after the minoxidil is stopped; minoxidil inhibits collagen production, possibly accelerating skin aging; serious allergic reactions including rash, chest distress, chest pain, dizziness, tachycardia and the like may occur; existing therapeutic agents are not very successful and often have undesirable side effects, profoundly afflicting both patients and dermatologists; therefore, the development of effective oleanolic acid external preparations is very important.
Oleanolic acid is almost insoluble in water (solubility in water: 4.61mg/L at 25 ℃), has poor cell permeability, and belongs to class VI drugs, i.e., low-solubility and low-permeability drugs, according to the classification system of biopharmaceuticals. Furthermore, the solubility and the dissolution efficiency of the oleanolic acid in common alcohols, fatty acids, surfactants and other fat-soluble solvents are poor, so that the application of the oleanolic acid is greatly limited. The selection of the proper formulation or solvent is critical to increase the solubility of oleanolic acid, since only the dissolved drug can penetrate the skin.
The patents on oleanolic acid formulations have been disclosed to improve the dispersibility of oleanolic acid in water, but there are still some problems that the industrial production and use in large scale are hindered, such as low content of oleanolic acid, the involvement of organic solvents harmful to human skin or health, or complicated processing steps.
For example, chinese patent CN101991532B discloses a non-aqueous self-microemulsion composition, said self-microemulsion composition contains oleanolic acid 0.4-20 mg/ml, said oil phase is one or more of the following: soybean oil, isopropyl myristate, isopropyl palmitate, ethyl laurate, ethyl myristate, glyceryl oleate, glyceryl linoleate, corn oil, sesame oil, olive oil and caprylic capric glyceride, wherein the content of the oil phase is 30-56%; oleanolic acid is solubilized by said co-surfactant/solvent and is selected from the group consisting of glycerol, polyethylene glycol, propylene glycol, ethylene glycol monoethyl ether, absolute ethanol, dimethylacetamide and N-methylpyrrolidone; in example 22, in which the oleanolic acid content is up to 20mg/mL, the total surfactant content is up to 66%, the content of the main solvent N-methylpyrrolidone (NMP) is 25%, but N-methylpyrrolidone (NMP) has the hazards of irritation, reproductive toxicity and the like, and dimethylacetamide, which is a more efficient solvent, has obvious irritation and toxicity to human bodies and skins, is teratogenic and is not suitable for long-term use in high concentration.
Chinese patent application No. CN03125480.2 discloses an emulsion for injection of oleanolic acid and a preparation method thereof, comprising: 0.08-2 g/l of oleanolic acid, 5-30 g/l of phospholipid for injection, 50-200 g/l of soybean oil for injection, 22-25 g/l of glycerol and the balance of water for injection. The preparation method comprises mixing oleanolic acid and soybean oil to obtain oil phase; mixing phospholipid, glycerol and water for injection, and stirring to obtain water phase; adding the oil phase into the water phase under stirring, adjusting the pH value to 6.5-7.0, and adding water for injection to obtain coarse emulsion; homogenizing the crude milk with a high pressure homogenizer to obtain emulsion. The patent adopts the traditional method of mixing and homogenizing oil phase and water phase to prepare emulsion, the grain diameter of the prepared emulsion is larger and is about 1 mu m; and the oleanolic acid content is low, the dissolving process is time-consuming, and the process is complex.
Chinese patent CN2011800558173A relates to a soluble cosmetic composition, which uses nano-liposomes to embed oleanolic acid to enhance the percutaneous absorption of oleanolic acid and promote the synthesis of collagen, thereby improving the anti-wrinkle effect; the preparation method comprises mixing surfactant such as hydrogenated lecithin, PEG-60 hydrogenated castor oil, etc. with polyalcohol component, heating to 80 deg.C for dissolving, adding 0.05% oleanolic acid and other additives, and mixing; the resulting mixture was cooled to 65 ℃ and then ethanol was added thereto; the ingredients of the aqueous part are mixed homogeneously and heated to 65 ℃ and mixed with the previously obtained mixture; the main disadvantages are that the preparation process is complex, multiple heating and cooling are needed, the cost is high, and the liposome stability is poor; in addition, no matter how the ratio of the surfactant, the polyol and the water is adjusted, the concentration of oleanolic acid is generally low, and the content is only 0.05% due to the dissolving capacity of the solvent.
In order to solve the problem of insufficient application of oleanolic acid, the present invention uses a pharmaceutical carrier nano emulsion (nanoemusion) in pharmacy. Nanoemulsions are defined as emulsion systems consisting of an oil phase with a surfactant and water, having an isotropic, transparent (or translucent) appearance. The droplet size is defined as less than 200nm. However, if the emulsion has a low surfactant content and is kinetically stable, then a size of less than 500nm may be accepted as a nanoemulsion. These nanocarriers are transparent, low viscosity, thermodynamically stable, easy to prepare, and high surface area making them effective transdermal and topical drug delivery systems; moreover, they have substantial advantages over other nanocarriers (e.g., microemulsions, liposomes), including the use of less surfactant, low skin irritation, high permeability and high drug loading, allowing topical treatment. The nanoemulsions can be used as starting materials for the preparation of nanocapsules and nanospheres, and can be formulated into various topical dosage forms, such as foams, gels, creams, liquids and sprays. Although the size of microemulsions and nanoemulsions is similar, their preparation methods are different. Both of them require energy input, but nanoemulsions mostly use mechanical shear, while microemulsions use a spontaneous emulsification process. Microemulsions also require high surfactant concentrations compared to nanoemulsions.
The nanometer emulsion gel is prepared by adding water soluble polymer materials such as carbomer, poloxamer, gelatin, cellulose, etc. into nanometer emulsion to form transparent and stable colloid with network structure. The nanoemulsion gel can improve the viscosity of the nanoemulsion, improve the adhesion and the spreadability of the nanoemulsion on the skin, and can ensure that the drug can keep longer action time because the diffusion of the drug in the gel is hindered, the effective diffusion coefficient is reduced and the volatilization of components is reduced due to the increase of the viscosity of the system. Is beneficial to the full absorption of the medicine, thereby improving the bioavailability of the medicine, and has convenient and sanitary administration, difficult pollution to clothes and better patient compliance.
Disclosure of Invention
The invention aims to provide a high-concentration oleanolic acid nanoemulsion composition and a preparation method thereof aiming at the defects in the prior art.
Another object of the present invention is to provide the use of said oleanolic acid nanoemulsion composition.
The oleanolic acid nanoemulsion composition comprises the following components in percentage by weight:
0.01-8% of oleanolic acid, 1-40% of surfactant, 1-40% of cosurfactant, 0.2-20% of essential oil containing terpene, 0-2% of baicalin, 0-5% of oleuropein, a proper amount of additive and the balance of water.
Preferably, the oleanolic acid nanoemulsion composition comprises the following components in percentage by weight:
0.5-2% of oleanolic acid, 10-30% of surfactant, 10-25% of cosurfactant, 1-10% of terpene-containing essential oil, 0.1-1% of baicalin, 0.5-2% of oleuropein, a proper amount of additive and the balance of water.
The oleanolic acid can be pure product or plant extract containing oleanolic acid; the plant extract contains at least 2% of oleanolic acid, and can be selected from fructus Ligustri Lucidi extract, herba Swertiae Bimaculatae extract, herba Swertiae Mileensis extract, and Olea Europaea extract.
The surfactant is preferably a nonionic surfactant; the HLB value of the surfactant can be 8-18, preferably 10-15; the surfactant may be at least one selected from PEG-6 caprylic/capric glyceride, PEG-8 caprylic/capric glyceride, tween 80, tween 20, polyoxyethylene 40 hydrogenated castor oil, polyoxyethylene castor oil, glyceryl monostearate, span 80, glyceryl monostearate, hydrogenated lecithin, steareth, polyethylene glycol stearate, polyglycerol fatty acid ester, and the like.
The cosurfactant can be at least one of diethylene glycol monoethyl ether, dipropylene glycol, 1, 3-butanediol, ethanol, 1, 2-pentanediol, 1, 2-hexanediol, propylene glycol, glycerol, polyethylene glycol and the like; diethylene glycol monoethyl ether is preferred.
Wherein the terpene-containing essential oil contains terpenes structurally belonging to the group of monoterpenes, sesquiterpenes, diterpenes or triterpenes in an amount of at least 1% by weight of the terpene-containing essential oil, more preferably at least 10% by weight of the terpene-containing essential oil. Terpene-containing essential oils include, but are not limited to, cedar essential oil, eucalyptus essential oil, mint essential oil, tea tree essential oil, lavender essential oil, clary sage essential oil, clove bud essential oil, cedar essential oil, geranium essential oil, lemon grass essential oil, sage essential oil, turmeric essential oil, wintergreen essential oil, rosemary essential oil, fennel essential oil, chamomile essential oil, guaiacum essential oil, fennel essential oil, basil essential oil, camphor essential oil, cananga essential oil, citronella essential oil, cinnamon essential oil, ginger essential oil, perilla essential oil, rose essential oil, patchouli essential oil, sandalwood essential oil, bay leaf essential oil, carrot seed essential oil, bergamot essential oil, grapefruit essential oil, lemon essential oil, citrus essential oil, orange flower essential oil, oregano essential oil, sweet orange essential oil, thyme essential oil, and other suitable essential oils.
The terpene-containing essential oil is preferably at least one selected from eucalyptus oil, tea tree essential oil, cedar essential oil, peppermint essential oil, lavender essential oil, rosemary essential oil, etc.; the terpene-containing essential oil comprises, by weight, 0.2% -10% of eucalyptus oil, 0.2% -10% of tea tree essential oil, 0.3% -5% of cedar essential oil, 0.8% -3.2% of mint essential oil, 0.6% -2.4% of lavender essential oil and 0.5% -3.2% of rosemary essential oil, and preferably: eucalyptus oil 0.3-12%, tea tree essential oil 0.3-10%, cedar essential oil 0.3-5%, peppermint essential oil 0.8-3.2%, lavender essential oil 0.6-2.4%, rosemary essential oil 0.5-3.2%; more preferably: eucalyptus oil 0.5-2%, tea tree essential oil 0.5-2%, cedar essential oil 0.3-1%, peppermint essential oil 0.8-2.0%, lavender essential oil 0.5-1.2%, rosemary essential oil 0.5-1.6%.
The additives may include thickeners, humectants, pH adjusters, preservatives, antioxidants, conditioning agents, chelating agents, uv absorbers, nutrients, or other suitable additives. The other suitable additives include, but are not limited to, at least one of an emollient, an anti-androgen agent, a hair growth agent, and the like.
The thickener is selected from carbomer, hydroxyethyl cellulose, sodium carboxymethylcellulose, sodium alginate, polycarbophil, poloxamer, xanthan gum, aloe vera gum, guar gum, polyquaternium Q-10, acrylic acid, and acrylate; carbomers are preferred; the usage amount of the thickener is preferably 0.1 to 5 percent of the total weight of the nanoemulsion;
the humectant can be at least one selected from Astragalus polysaccharides, sodium hyaluronate, dipotassium glycyrrhizinate, glycerol, polyethylene glycol, sorbitol, maltitol, aloe gel, sodium lactate, squalane, etc.; preferably astragalus polysaccharides and sodium hyaluronate; the usage amount of the humectant is preferably 0.5-5% of the total weight of the nanoemulsion.
The pH modifier may be selected from citric acid, malic acid, lactic acid, phosphoric acid, triethanolamine, and combinations thereof, preferably triethanolamine; the usage amount of the pH regulator is preferably 0.1-1% of the total weight of the nanoemulsion.
The preservative can be selected from p-hydroxyacetophenone, phenoxyethanol, benzoic acid, caprylhydroxamic acid, caprylyl glycol, methyl paraben, ethyl paraben, propyl paraben, butyl paraben, dimethylaminoethanol, benzalkonium chloride, benzalkonium bromide and the like, and the usage amount of the preservative is preferably 0.1-0.6% of the total weight of the nanoemulsion.
The antioxidant is selected from one or more of sodium bisulfite, vitamin E, vitamin C, lauryl gallate, propyl gallate, caffeic acid phenethyl ester, arbutin, ferulic acid, ascorbic acid magnesium phosphate, ascorbic acid sodium phosphate, and ascorbic acid ethyl ether.
The conditioner is one or more of allantoin, dipotassium glycyrrhizinate, tocopherol acetate, baicalein, olive leaf extract, scutellaria baicalensis extract, lavender extract, chamomile extract, witch hazel extract, purslane extract, gentian root extract and rosemary extract.
The chelating agent is selected from EDTA, EDTA-2Na or EDTA-4Na.
The ultraviolet absorbent is at least one selected from baicalin derivatives, quercetin derivatives, p-aminobenzoic acid derivatives, salicylic acid derivatives, benzophenone derivatives, diphenyl acrylate, cinnamic acid derivatives, etc.
The nutritional agent is at least one selected from lysine, cystine, arginine, collagen, biotin, chondroitin sulfate, keratan sulfate, heparin sulfate, polypeptide, vitamin A, B1, B2, B6, E, C and vitamin C derivatives.
The emollient is selected from cetostearyl alcohol, lanolin, isopropyl isostearate, vaseline, liquid paraffin, polydimethylsiloxane, dimethiconol, dimethicone, shea butter, cetyl isooctanoate, natural squalane, octyl methoxycinnamate.
The antiandrogen agent is selected from at least one of finasteride, dutasteride, epristeride, flutamide, bicalutamide, safflor yellow, equol, soybean isoflavone, ligustilide, hinokiflavone, saw palmetto extract, sophora flavescens extract, salvia miltiorrhiza extract, lavender extract, genistein, turmeric extract, emblic leafflower fruit extract, nettle extract, speranskia herb extract, ganoderma lucidum extract, dittany bark extract, azelaic acid, quercetin, myricetin, magnolol, luteolin, kaempferol, rutin, tea polyphenol, curcumin, emodin, baicalein, tea tree extract, pueraria radix extract, genistein, scutellaria root extract, spironolactone, cimetidine, cyproterone, hexestrol, 11-alpha-hydroxyprogesterone, diosolone, levonorgestrel, norethindrone, etc.
The pilatory can be one or more selected from Polygoni Multiflori radix extract, fructus Ligustri Lucidi extract, carthami flos extract, chinese arborvitae extract, herba Rosmarini officinalis extract, ginseng radix extract, notoginseng radix extract, green tea extract, herba Centellae extract, herba Swertiae Bimaculatae extract, semen Pisi Sativi extract, ginsenoside, radix Angelicae sinensis extract, olea europaea extract, radix astragali extract, rhizoma Ligustici Chuanxiong extract, rhizoma Zingiberis recens extract, semen Sesami Niger extract, semen Cuscutae extract, ecliptae herba extract, folium Mori extract, epigallocatechin gallate (EGCG), cedrol, stilbene glucoside, adenosine, caffeine, and minoxidil.
The water may be selected from distilled water, purified water and/or deionized water, preferably distilled water.
The additive of the oleanolic acid nanoemulsion composition of the present invention is usually such that the fat-soluble component is dissolved in the oil phase of the emulsification system and the hydrophilic component is dissolved in the water phase component of the emulsification system.
When the dosage form of the present invention is an ointment, paste, cream or gel, as a carrier ingredient, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or a mixture thereof may be used.
When the formulation of the present invention is a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof can be used as a carrier component, and particularly when the formulation is a spray, a propellant such as chlorofluorocarbon, propane/butane or dimethyl ether may be further included.
When the dosage form of the present invention is an emulsion, a liquid diluent such as water, ethanol or propylene glycol may be used as a carrier component.
The preparation method of the oleanolic acid nanoemulsion composition comprises the following steps of:
1) Adding the cosurfactant and the essential oil containing terpene into a container A according to the formula amount, and mixing and stirring uniformly; adding the surfactant with the formula amount, and uniformly mixing; then adding oleanolic acid with formula amount, and further adding other fat-soluble components (such as baicalin) and stirring to completely dissolve;
2) Adding water with the formula amount into the container B, and further adding a proper amount of additives to obtain a water phase;
3) Slowly adding the mixture in the container A into the water phase in the container B while stirring to obtain primary emulsion;
4) Carrying out high-speed shearing emulsification on the primary emulsion prepared in the step 3), carrying out secondary emulsification by using a high-pressure homogenizing emulsification device, and fully emulsifying to obtain the oleanolic acid nanoemulsion composition.
In the step 1), the mass ratio of the cosurfactant to the terpene-containing essential oil can be 4: 1-1: 1; the dissolution can be carried out at the normal temperature of 25-40 ℃ by stirring until the dissolution is complete, or the solution is heated and stirred under the condition of 40-80 ℃ water bath until the dissolution is complete;
in the step 4), the secondary emulsification is carried out by using a high-pressure homogenizing and emulsifying device, the homogenizing speed is 4000-10000 rpm, the homogenizing time is 3-10 min, the high-pressure homogenizing pressure is 800-1000 bar, and the homogenization is carried out for 3-5 times; the average particle size of liquid drops in the prepared oleanolic acid nanoemulsion composition can be 10-200 nm, and is preferably less than 100nm; the secondary emulsification can also adopt micro-jet emulsification or ultrasonic emulsification.
The composition of the present invention is used as a nanoemulsion, and the average particle diameter of the liquid droplet is preferably 10 nm to 200nm. The emulsification process can be selected from the following processes besides the preferred high-pressure homogenization: self-emulsification, ultrasonic emulsification or microfluidization, etc.; if self-emulsification is used, the primary emulsion is stirred and uniformly mixed to obtain the nano emulsion; if ultrasonic emulsification is used, the primary emulsion is subjected to ultrasonic treatment at normal temperature, the power is 0.1-75 KW, the frequency is 20 KHz-500 MHz, the interval is 3s when the ultrasonic treatment is carried out for 3-5 s, and the whole ultrasonic treatment time is 15-300 s; if the micro-jet is emulsified, the primary emulsion is added into a micro-jet high-pressure homogenizer, and is treated for three times by increasing the pressure, wherein the pressure is 1000bar, 1200bar and 1400bar in sequence, and then is filtered by an ultramicro filter membrane with the aperture of 100nm.
The oleanolic acid nanoemulsion composition can be applied to the preparation of cosmetics. The cosmetic includes, but is not limited to, hair tonic, hair growth lotion, hair conditioner essence, skin care gel, anti-aging preparation, shampoo, skin foundation, essence emulsion, lotion, toner, acne lotion, emulsion, microemulsion, shampoo, gel, perfume, hair wax, hair conditioner, hair mask, mascara, hair oil, massage oil, hair conditioner, hair-blacking agent, hair dye, hair spray, hair mousse, etc.
The oleanolic acid nanoemulsion composition is used in a medicine or a cosmetic for improving or preventing alopecia, hair thinning, canities, acne, seborrheic dermatitis, folliculitis, skin aging or other unhealthy skin conditions. The alopecia includes androgenetic alopecia, telogen effluvium, alopecia areata, or other types of alopecia.
The oleanolic acid nanoemulsion composition can be used for skin, hair, facial skin care and the like.
The oleanolic acid nanoemulsion composition can be added with an excipient to be used as a dosage form for skin or hair care, and the oleanolic acid nanoemulsion composition is used alone as a product, or is mixed with other cosmetic or pharmaceutical raw materials to be prepared into nanoemulsion gel, ointment, cream, emulsion, spray, lotion, liniment, patch or liniment.
In the embodiment of the invention, besides oleanolic acid and essential oil containing terpene as active ingredients, other functional ingredients such as baicalin can be added. Baicalin has effects of resisting skin allergy, resisting inflammation, inhibiting bacteria, preventing corrosion, and resisting oxidation, and can be used for preventing and treating skin allergy. Baicalin can absorb ultraviolet ray, remove oxygen free radical, and inhibit melanin generation, and has effects of antagonizing Androgen Receptor (AR), reducing gene expression of AR, and reducing alopecia and acne. Baicalin is extremely difficult to dissolve in various inorganic and organic solvents, has poor water solubility and lipid solubility, and can realize better dissolution and improve bioavailability and biological efficacy in the nanoemulsion system.
Embodiments of the nanoemulsion of the present invention as a cosmetic and/or pharmaceutical composition further comprise oleuropein (oleuropein). Oleuropein is a glycosylated terpenoid compound, is a main effective component of olive leaf extract, and has strong antibacterial and antiviral properties and strong antioxidant ability. It has been proved that topical application of oleuropein promotes collagen growth, and expression of VEGF, IGF-1, KGF and HGF is increased, and these growth factors are closely related to skin healing and hair growth, thus promoting hair growth, accelerating wound healing, soothing and calming the skin.
The present invention may further comprise astragalus polysaccharides as an example of a cosmetic and/or pharmaceutical composition. The astragalus polysaccharide has the functions of oxidation resistance and aging resistance, and simultaneously has good hygroscopicity, thereby playing the role of moisturizing and skin moistening; polysaccharides also have thickening effect, so that astragalus polysaccharides can be used as a thickening agent; in addition, the astragalus polysaccharide has the function of promoting hair regeneration, and has good synergistic effect with oleanolic acid.
Compared with the prior art, the invention has the outstanding advantages and technical effects that:
1. the particle size of the liquid drops in the oleanolic acid nanoemulsion is nano-scale, is less than 200nm, is spherical and is very uniform in distribution, and the defects that the particle size of the traditional emulsion is large and the thermodynamic stability is poor are overcome: the dispersibility of the oleanolic acid in water is remarkably improved, the solubility of the oleanolic acid is improved by more than 10000 times, and the bioavailability of the oleanolic acid is improved. The oleanolic acid nanoemulsion composition disclosed by the invention can greatly improve the solubility and the dissolution rate of oleanolic acid, can improve the drug loading rate after being prepared into a dosage form, improves the treatment or improvement effect, and is beneficial to the application of oleanolic acid in cosmetics and external medicinal preparations.
2. The positive characteristics (namely physiological activity) of the oleanolic acid are combined with the essential oil containing terpene, which has good transdermal absorption capacity and nutrition or healing effect, and the combination of the two has excellent synergistic effect; the two are combined by intermolecular forces, the essential oil containing terpene enhances dissolution and transdermal absorption of oleanolic acid, the oleanolic acid reduces volatilization of the essential oil, and reduces or prevents sensitization of the essential oil to individual skin sensitive individuals.
3. The oleanolic acid nanoemulsion of the invention is a dispersion system which is isotropic, good in fluidity, clear, transparent or semitransparent and slightly opalescent under the combined action of the essential oil, the surfactant and the cosurfactant, can still keep clear after being diluted by water, has good organoleptic property, can reduce viscosity and greasiness when the essential oil is used as an oil phase, has natural plant fragrance, and is excellent in actual use comfort.
4. The anti-corrosion capability of the product is improved, and the anti-corrosion additive is reduced or even not added. The essential oil used by the nanoemulsion has the antibacterial and antiseptic effect, and the oleanolic acid also has the strong antibacterial effect, so that the product can be prevented from deteriorating without adding a chemical preservative, the irritation to the skin is reduced, and the safety is improved.
5. Oleanolic acid is actually able to penetrate the skin to be effective, and must be able to penetrate the stratum corneum barrier of the skin to reach the relevant site of action and maintain the effect at these sites for a certain period of time. The nano-emulsion has small particle size, is beneficial to the transdermal absorption of functional components and plays a role; one or more natural plant essential oils with permeation promoting effect are used, and no chemical permeation promoter is needed, so that the percutaneous absorption capability of oleanolic acid and other active ingredients in the composition is improved, and the safety is better; the nano-emulsion contains water, has better skin hydration property and is more beneficial to absorption.
6. The product has simple preparation process and is beneficial to environmental protection. The traditional emulsion cosmetics or external medical preparations need to use a plurality of raw materials, the oil phase and the water phase have complex components, a plurality of additives, complicated process flow and longer production period, or toxic and harmful solvents are used for improving the dissolving amount of the oleanolic acid; the preparation process can be carried out at room temperature, has stable compatibility with active ingredients, can contain essential oil and other additives without denaturation, and has the advantages of simple preparation components, low cost, simple preparation process, easy industrial production and reduced environmental pollution.
Drawings
Fig. 1 is a product appearance diagram of the oleanolic acid nanoemulsion compositions prepared in examples 1-6.
Fig. 2 is a comparative graph of groups after experimental effect of oleanolic acid nanoemulsion on androgen alopecia model mice.
Wherein A is a blank group; b is a model group; c is minoxidil group; d is 1% oleanolic acid group (group 4); e is oleanolic acid + oleuropein + baicalin group (group 5).
Detailed Description
The following examples further illustrate the invention in conjunction with the drawings. The exemplary compositions are illustrative only and do not limit the scope of the invention. The proportions in the examples and other parts of the specification are by weight unless otherwise indicated. The following formulations are directed to the nanoemulsion, gel embodiments; however, similar techniques may also be used with the formulation in other types of cosmetic or toiletry products, including but not limited to shampoos, creams, sprays, conditioners, and styling products.
The invention relates to a nano-emulsified carrier of oleanolic acid. Terpenoids refer to derivatives with the general formula of (C5H 8) n and their oxygen-containing and different saturation levels, which are widely found in nature, monoterpenes and sesquiterpenes, which are widely found in plant essential oils, oleanolic acid (oleanolic acid) is a pentacyclic triterpenoid, which is a terpene. Based on the principle of similarity and compatibility, the solubility of the essential oil aligned with the oleanolic acid arouses the interest of the inventor; many terpene-containing plant essential oils, oleanolic acid, have surprising solubilizing effects as determined by the present invention, such as eucalyptus oil, tea tree essential oil, cedar essential oil, lavender essential oil, rosemary essential oil, mint essential oil, lemon essential oil, carrot seed oil, and the like; in addition, liquid terpene monomers contained in a large amount in some essential oils, such as Eucalyptol (Eucalyptol) of eucalyptus oil and rosemary oil, terpin-4-ol (terpin-4-ol) of tea tree oil, linalool (linalool) of lavender essential oil, geraniol (Geraniol) of rose essential oil, and the like, have excellent solubility of oleanolic acid.
Applicants have found that nanoemulsions of terpene containing essential oils as the oil phase are suitable bases for oleanolic acid. Thus, the positive properties of oleanolic acid are combined with a nanoemulsion comprising terpene containing essential oils. In particular, nanoemulsions with high oleanolic acid drug loading can be produced, which combine the positive properties of oleanolic acid (i.e. physiological activity) with terpene containing essential oils with good transdermal absorption capacity and nutritional or healing efficacy (if any). This makes the nanoemulsion formulation particularly suitable for cosmetic or dermatological formulations of triterpenoids.
The preparation method is characterized in that a mixture of a cosurfactant and terpene-containing essential oil in a mass ratio of 4: 1-1: 1 is used for solubilizing the oleanolic acid: not only can prevent coagulation in the middle of dissolution, but also can greatly improve the concentration of oleanolic acid in the preparation.
In embodiments of the present invention, novel utilities and/or advantages may be provided when essential oils are both the carrier and solvent as well as the active ingredient; the invention encapsulates essential oil in a nano system to be used as an oil phase, can improve the solubility of oleanolic acid, and can play a synergistic role with active ingredients in application.
The essential oils of the examples of the present invention have a number of valuable properties which can be used as a combination therapy; plant essential oils are useful in dermatological patients, and they generally have antibacterial, antifungal, anti-inflammatory, astringent and regenerative properties; can be used for aromatherapy, and for treating dandruff, psoriasis, eczema, acne, seborrheic dermatitis, etc.; have a very beneficial synergistic effect as active ingredient and/or enhancer in the intended application, in particular as androgen antagonist and hair growth promoter; essential oils such as eucalyptus oil, peppermint oil, tea tree oil, and the like have been widely studied and reported as permeation enhancers for enhancing transdermal drug delivery; in addition, the encapsulation of the nanosystems can provide controlled release of bioactive ingredients such as oleanolic acid, and provide better stability of essential oils and other volatile compounds, enhancing bioavailability and bioefficacy of the formulation.
And from a toxicological point of view, essential oils are considered safer and less irritating than other chemical penetration enhancers; essential or non-volatile oils extracted from aromatic plants are widely used in food, cosmetics and pharmaceuticals, and many are listed in the General Recognized As Safe (GRAS) list of the FDA in the united states, i.e., the "Recognized Safe compounds", essential oils, oleoresins (without solvents) and natural extracts (including distillates) are Generally considered Safe for the intended use (food, cosmetics), such as menthol, peppermint, rosemary, sage, orange blossom, lemon GRASs, thyme, orange leaf, citronella, ylang-ylang, etc., and are not dangerous and suitable for long-term use.
Eucalyptus oil is also called eucalyptus essential oil, has the functions of antibiosis, antioxidation, anti-inflammation, permeation promotion, disinsection, mosquito repelling, itching relieving and corrosion prevention, is a good raw material of medicine and perfume, and is widely used in food processing and cosmetics. Eucalyptus oil is also used to improve the blood circulation of the scalp, thereby promoting hair growth.
The tea tree essential oil has strong cleaning, antibacterial, anti-inflammatory and antiseptic properties, is suitable for oily and acne skin, and can be used for treating suppurative wound, burn, sunburn, psoriasis, dandruff, etc. In addition, the tea tree essential oil has weak estrogen-like activity, and in vitro researches prove that the expression of androgen receptor can be reduced, so that androgenetic alopecia can be reduced.
It is well known that peppermint essential oil produces a cool feeling and promotes blood circulation, helps to reduce skin inflammation and itching, and is confirmed to promote hair growth.
Cedrol, a main component of cedar essential oil, is also a main active component of cacumen biotae, and has a vasodilating effect on blood vessels, so that new hair growth can be stimulated by hair follicles, and meanwhile, the natural shedding process is inhibited. In addition, the cedar essential oil has strong antifungal and antibacterial properties, and the addition of the cedar essential oil in the treatment of acne is helpful for relieving and reducing stubborn acne outbreaks.
Lavender essential oil has been shown to have weak estrogenic activity and very strong anti-inflammatory properties, and may play a key role in helping users relieve itching and swelling of the skin, increasing the speed of wound healing, and thus providing a good environment for skin repair and hair growth.
Rosemary essential oil has strong astringent effect, and can improve greasy desquamation skin, promote blood circulation, and stimulate hair regeneration.
In some embodiments, the composition may include other additives, such as thickeners, humectants, pH adjusters, stabilizers, preservatives, antioxidants, conditioning agents, emollients, colorants, skin protectants, skin and hair nutrients such as collagen, elastin, keratin and other suitable additives.
In some embodiments, the composition comprises a humectant selected from one or more of astragalus polysaccharides, sodium hyaluronate, dipotassium glycyrrhizinate, glycerin, aloe vera gel, more preferably astragalus polysaccharides and sodium hyaluronate;
in some embodiments, the composition may further comprise a thickening agent, such as a naturally derived thickening agent, for example carbomer, hydroxyethyl cellulose, sodium carboxymethyl cellulose, sodium alginate, poloxamer 407, xanthan gum, guar gum, more preferably carbomer.
In some embodiments, the composition may further comprise a pH adjusting agent, which may be selected from citric acid, malic acid, lactic acid, phosphoric acid, triethanolamine, and combinations thereof, preferably triethanolamine.
In some embodiments, no preservative may be added to the composition, for example, the essential oil and 1, 3-butanediol, ethanol, 1, 2-pentanediol, 1, 2-hexanediol all have preservative and bacteriostatic effects; in some embodiments, small amounts of preservatives including p-hydroxyacetophenone and phenoxyethanol may optionally be used.
The compositions of the present invention are hydrophilic in nature. The water may be distilled, purified and/or deionized water, preferably distilled water. In some embodiments, the composition comprises about 1% to 80% by weight water.
The average particle size of liquid drops in the oleanolic acid nanoemulsion composition is 10-200 nm, and the particle size of the nanoemulsion is preferably less than 100nm. The application process can be one or more of high-pressure homogenization in high-energy emulsification, micro-jet or ultrasonic, and preferably high-pressure homogenization.
The obtained nanoemulsion can be used alone, or can be further added with other excipients to be prepared into nanoemulsion gel, cream, emulsion, spray, transdermal patch, paste dosage forms and the like.
According to the preparation method of the present invention, terpene-containing essential oils such as eucalyptus oil, tea tree oil, cedar oil and the like have a high solubility to oleanolic acid, but when the amount of oleanolic acid dissolved in the essential oils exceeds 40mg/mL, white colloidal coagulation is easily formed, which seriously hinders further dissolution.
The preparation method is characterized in that a mixture of a cosurfactant and terpene-containing essential oil in a mass ratio of 4: 1-1: 1 is used for solubilizing oleanolic acid: not only can prevent condensation during dissolution, but also can greatly improve the concentration of oleanolic acid in the preparation;
in embodiments of the present invention, novel utilities and/or advantages may be provided when essential oils are both the carrier and solvent as well as the active ingredient; the invention encapsulates essential oil in a nano system to be used as a lipophilic phase, can improve the solubility of oleanolic acid, and can play a synergistic effect with active ingredients in application.
The oleanolic acid nanoemulsion composition of the present invention may further include other hydrophilic or lipid-soluble active ingredients, thereby providing a cosmetic or external preparation with stronger activity. Generally, a fat-soluble active ingredient is dissolved in an oil phase of an emulsification system, and a hydrophilic ingredient is dissolved in an aqueous phase of the emulsification system. It should be noted that the active ingredients include baicalin with antiandrogen effect, and other active ingredients such as oleuropein and Astragalus polysaccharides. The formulation of the nano-emulsion composition of the present invention is embodied in the form of nano-emulsion, essence, gel or shampoo, etc., and thus, the nano-emulsion of the present invention further comprises auxiliary components of these forms, such as thickener, humectant, preservative, etc.
In the embodiment of the invention, in addition to oleanolic acid and terpene-containing essential oil as active ingredients, other active ingredients and/or enhancers such as baicalin may be added. Other active ingredients and/or enhancers such as baicalin may also be added in embodiments of the present invention. Baicalin is known to have anti-skin allergy, anti-inflammatory, bacteriostatic, antiseptic, and antioxidant effects, and can be used for preventing and treating skin allergy. Baicalin can absorb ultraviolet ray, remove oxygen free radical, and inhibit melanin generation, and has effects of antagonizing Androgen Receptor (AR), reducing gene expression of AR, and reducing alopecia and acne. Baicalin is extremely insoluble in various inorganic and organic solvents, has poor water solubility and lipid solubility, and can be well dissolved and improve bioavailability and biological efficacy in the nanoemulsion system.
Embodiments of the nanoemulsion of the present invention as a cosmetic and/or pharmaceutical composition further comprise oleuropein (oleuropein). Oleuropein is a glycosylated terpenoid compound, is a main effective component of olive leaf extract, and has strong antibacterial and antiviral properties and strong antioxidant capacity. It has been proved that topical application of oleuropein promotes collagen growth, and expression of VEGF, IGF-1, KGF and HGF is increased, and these growth factors are closely related to skin healing and hair growth, thus promoting hair growth, accelerating wound healing, soothing and calming the skin.
The present invention may further comprise astragalus polysaccharides as an example of a cosmetic and/or pharmaceutical composition. The astragalus polysaccharide has the functions of oxidation resistance and aging resistance, and also has good hygroscopicity, thereby playing the role of moisturizing and skin moistening; polysaccharides also have thickening effect, so that astragalus polysaccharides can be used as a thickening agent; in addition, the astragalus polysaccharide has the function of promoting hair regeneration, and has good synergistic effect with oleanolic acid. Other plant extracts having hair growth promoting and antiandrogen effects, such as ginsenoside, ginseng extract, polygonum multiflorum extract, rosemary extract, safflower extract, biota orientalis extract, scutellaria baicalensis extract, and the like, may be added to the preparation of the present invention.
Because the quality standards of the same functional ingredients and raw materials are not completely the same at present, and especially the solubility of the active ingredients is influenced by the difference of the content and the purity of essential oil ingredients, great care must be taken to the quality and the source of the raw materials when the product is prepared. In the embodiment of the invention, the content of eucalyptol in eucalyptus oil is more than or equal to 80 percent, the content of terpinen-4-ol (terpin-4-ol) in tea tree oil is more than or equal to 42 percent, the content of linalool in lavender essential oil is more than or equal to 31 percent, the content of eucalyptol in rosemary essential oil is more than or equal to 26 percent, the content of cedrol in cedar essential oil is more than or equal to 11 percent, the mint essential oil is peppermint essential oil, and the content of menthol is more than or equal to 36 percent; the purity of diethylene glycol monoethyl ether is more than or equal to 99.5 percent, is in cosmetic grade or pharmaceutical grade, and is preferably Transcutol CG or Transcutol HP.
Specific examples are given below.
Example 1:
a1% oleanolic acid nanoemulsion comprises the following raw material components in percentage by weight, as shown in Table 1:
TABLE 1
Components | Weight percent (%) |
Oleanolic acid | 1 |
Eucalyptus oil | 1 |
Tea tree oil | 2 |
Rosemary essential oil | 1.2 |
Mint essential oil | 2 |
Lavender essential oil | 0.8 |
Diethylene glycol monoethyl ether (Transcutol) | 16 |
Dipropylene glycol | 5 |
Tween 20 | 25.00 |
Polyoxyethylene 35 castor oil | 8 |
Distilled water | 37.8 |
The preparation method comprises the following steps:
(1) weighing eucalyptus oil, tea tree oil, rosemary essential oil, mint essential oil and lavender essential oil according to the formula ratio, and uniformly mixing the eucalyptus oil, the tea tree oil, the rosemary essential oil, the mint essential oil and the lavender essential oil with diethylene glycol monoethyl ether and dipropylene glycol in a container A.
(2) Weighing the Tween 20 and the polyoxyethylene 35 castor oil according to the formula amount, adding the Tween 20 and the polyoxyethylene 35 castor oil into the mixture in the container A, uniformly mixing, adding the oleanolic acid according to the formula amount, and stirring until the oleanolic acid is completely dissolved.
(3) Adding distilled water into the container B, and then adding and uniformly mixing.
(4) Adding the mixture in the container A into the container B under the stirring state to obtain primary emulsion, and then carrying out secondary emulsification by using a high-pressure homogenizing and emulsifying device, wherein the homogenizing speed is 5000rpm, the homogenizing time is 5min, the high-pressure homogenizing pressure is 800bar, and the homogenizing is carried out for 3-5 times.
(5) And (3) closing the high-pressure homogenizer, taking a small amount of finished products for observation, and obtaining the oleanolic acid nanoemulsion if the appearance is transparent or semitransparent, the fluidity and the dispersibility are good, and obvious visible opalescence is available.
Example 2:
a1% oleanolic acid nanoemulsion comprises the following raw material components in percentage by weight as shown in Table 2:
TABLE 2
Components | Weight percent (%) |
Oleanolic acid | 1 |
Eucalyptus oil | 2 |
Tea tree oil | 2 |
Lavender essential oil | 1.2 |
Mint essential oil | 1.8 |
Dipropylene glycol | 5 |
Ethanol | 3 |
1, 2-hexanediol | 8 |
PEG-6 caprylic/capric glycerides | 16 |
Polyoxyethylene 35 castor oil | 12 |
Biotin | 0.5 |
Glycyrrhizic acid dipotassium salt | 0.5 |
Distilled water | 47 |
The preparation method comprises the following steps:
(1) weighing eucalyptus oil, tea tree oil, mint essential oil, lavender essential oil, 1, 2-hexanediol, ethanol, dipropylene glycol, PEG-6 caprylic/capric glyceride and polyoxyethylene 35 castor oil according to the formula ratio, and uniformly mixing in a container A.
(2) Weighing oleanolic acid with the formula ratio, adding the oleanolic acid into the mixture in the container A, and heating and stirring the mixture in a water bath at 80 ℃ until the oleanolic acid is completely dissolved.
(3) Adding distilled water into the container B, adding biotin and dipotassium glycyrrhizinate, and stirring until the mixture is dissolved.
(4) Adding the mixture in the container A into the container B under the stirring state to obtain primary emulsion, and then carrying out secondary emulsification by using a high-pressure homogenizing and emulsifying device, wherein the homogenizing speed is 4000rpm, the homogenizing time is 5min, the high-pressure homogenizing pressure is 800bar, and the homogenizing is carried out for 3-5 times.
(5) And (3) closing the high-pressure homogenizer, taking a small amount of finished products for observation, and obtaining the oleanolic acid nanoemulsion if the appearance is colorless, and the finished products have good fluidity and dispersibility and obvious visible opalescence.
Example 3:
the 5% oleanolic acid nanoemulsion comprises the following raw material components in percentage by weight as shown in table 3:
TABLE 3
Components | Weight percent (%) |
Oleanolic acid | 5 |
Eucalyptus oil | 12 |
Tea tree oil | 8 |
Diethylene glycol monoethyl ether (Transcutol) | 36 |
PEG-8 caprylic/capric glycerides | 36 |
Distilled water | 3 |
The preparation method comprises the following steps:
(1) the eucalyptus oil, the tea tree oil, diethylene glycol monoethyl ether (Transcutol) and PEG-8 caprylic/capric glyceride with the formula ratio are weighed and added into a container A to be uniformly mixed.
(2) Adding oleanolic acid into the mixture according to the formula amount, placing the mixture into a water bath at 60 ℃, heating and stirring until the oleanolic acid is completely dissolved.
(3) Distilled water was added to vessel B, and then the mixture of vessel a was slowly added to vessel B with stirring to obtain a primary emulsion.
(4) And then, carrying out secondary emulsification by using a high-pressure homogenizing and emulsifying device, wherein the homogenizing speed is 4000rpm, the homogenizing time is 3min, the high-pressure homogenizing pressure is 800bar, and the homogenizing is carried out for 3-5 times.
(5) And (3) closing the high-pressure homogenizer, taking a small amount of finished products for observation, and obtaining the oleanolic acid nanoemulsion if the appearance is colorless, and the finished products have good fluidity and dispersibility and obvious visible opalescence.
Example 4:
the oleanolic acid nanoemulsion for promoting hair growth comprises the following raw material components in percentage by weight as shown in table 4:
TABLE 4
Components | Percentage by weight (%) |
Oleanolic acid | 1 |
Oleuropein | 1.6 |
Baicalin | 0.5 |
Tea tree oil | 2 |
Eucalyptus oil | 1 |
Rosemary essential oil | 1.2 |
Mint essential oil | 1.6 |
Lavender essential oil | 0.4 |
Cedar essential oil | 0.2 |
1,2 pentanediol | 5 |
Diethylene glycol monoethyl ether (Transcutol) | 23 |
Astragalus polysaccharides | 1 |
EDTA-4Na | 0.1 |
P-hydroxyacetophenone | 0.3 |
Arginine | 0.6 |
Polyoxyethylene 30 castor oil | 7 |
Tween 80 | 12 |
Polyoxyethylene 40 hydrogenated castor oil | 16 |
Distilled water | 25.5 |
The preparation method comprises the following steps:
(1) respectively weighing eucalyptus oil, tea tree oil, peppermint essential oil, lavender essential oil, rosemary essential oil, cedar essential oil, dipropylene glycol and diethylene glycol monoethyl ether (Transcutol) according to the formula ratio, and uniformly mixing in a container A.
(2) Weighing polyoxyethylene 30 castor oil, tween 80 and polyoxyethylene 40 hydrogenated castor oil according to the formula ratio, uniformly mixing, adding into the mixture in the container A, adding oleanolic acid and baicalin, and heating and stirring in a water bath at 80 ℃ until the oleanolic acid and the baicalin are completely dissolved.
(3) Adding distilled water into container B, adding oleuropein, astragalus polysaccharides, EDTA-4Na, arginine and p-hydroxyacetophenone, and stirring to dissolve.
(4) Adding the mixture in the container A into the container B under the stirring state to obtain primary emulsion, and then carrying out secondary emulsification by using a high-pressure homogenizing and emulsifying device, wherein the homogenizing speed is 5000rpm, the homogenizing time is 5min, the high-pressure homogenizing pressure is 800bar, and the homogenizing is carried out for 3-5 times.
(5) And (3) closing the high-pressure homogenizer, taking a small amount of finished products for observation, and obtaining the oleanolic acid nanoemulsion if the appearance is brown, semitransparent, good in fluidity and dispersibility and obvious in visible opalescence.
Example 5:
the oleanolic acid skin care nanoemulsion comprises the following raw material components in percentage by weight as shown in table 5:
TABLE 5
Components | Weight percent (%) |
Oleanolic acid | 0.5 |
Oleuropein | 1 |
Baicalin | 0.2 |
Tea tree oil | 0.7 |
Eucalyptus oil | 0.5 |
Mint essential oil | 1.2 |
Mint essential oil | 0.5% |
Lemon essential oil | 0.2% |
1, 2-hexanediol | 3 |
Dipropylene glycol | 3 |
Diethylene glycol monoethyl ether (Transcutol) | 8 |
PEG-8 caprylic/capric glycerides | 12 |
Polyoxyethylene 40 hydrogenated castor oil | 15 |
Glyceryl monostearate | 3 |
Hyaluronic acid sodium salt | 1 |
Vitamin C | 0.7 |
Aloe gel | 0.3 |
Phenoxyethanol | 0.3 |
EDTA-2Na | 0.1 |
Distilled water | 57 |
The preparation method comprises the following steps:
(1) respectively weighing tea tree oil, eucalyptus essential oil, lemon essential oil, 1, 2-hexanediol, dipropylene glycol and diethylene glycol monoethyl ether (Transcutol) according to the formula amount, and uniformly mixing in a container A.
(2) Weighing polyoxyethylene 30 castor oil, tween 80 and polyoxyethylene 40 hydrogenated castor oil according to the formula ratio, adding into the mixture in the container A, adding oleanolic acid and baicalin, and heating and stirring in a water bath at 60 ℃ until the mixture is completely dissolved.
(3) Adding distilled water into container B, adding oleuropein, phenoxyethanol, EDTA-2Na, and vitamin C, stirring to dissolve, adding sodium hyaluronate and aloe gel, and standing for 24 hr to swell completely.
(4) Adding the mixture in the container A into the container B under stirring to obtain primary emulsion, and then performing secondary emulsification by using a high-pressure homogenizing and emulsifying device, wherein the homogenizing speed is 6000rpm, the homogenizing time is 5min, the high-pressure homogenizing pressure is 800bar, and the homogenizing is performed for 3-5 times.
(5) And (3) closing the high-pressure homogenizer, taking a small amount of finished products for observation, and obtaining the oleanolic acid nanoemulsion if the appearance is light yellow, semitransparent, good in fluidity and dispersibility and has obvious visible opalescence.
Example 6:
the oleanolic acid acne-removing nanoemulsion gel comprises the following raw material components in percentage by weight as shown in table 6:
TABLE 6
The preparation method comprises the following steps:
(1) respectively weighing tea tree oil, peppermint essential oil, rosemary essential oil, cedar essential oil, 1, 3-butanediol and diethylene glycol monoethyl ether (Transcutol) according to the formula ratio, and uniformly mixing in a container A.
(2) Weighing polyoxyethylene 35 castor oil and tween 80 in the formula amount, adding into the mixture in the container A, adding oleanolic acid and baicalin, and heating and stirring in a water bath at 80 ℃ until completely dissolving.
(3) Adding distilled water into the container B, adding phenoxyethanol, EDTA-2Na and dipotassium glycyrrhizinate, and stirring until the materials are dissolved.
(4) And adding the mixture in the container A into the container B under the stirring state to obtain primary emulsion, and then carrying out secondary emulsification by using a high-pressure homogenizing and emulsifying device, wherein the homogenizing speed is 4000rpm, the homogenizing time is 6min, the high-pressure homogenizing pressure is 800bar, and the nano-emulsion is obtained after 3-5 times of homogenization.
(5) Slowly adding carbomer 940 into the nanoemulsion in a stirring state, adding triethanolamine, and standing at normal temperature for 24h to fully swell carbomer 940 to obtain transparent or semitransparent oleanolic acne removing nanoemulsion gel.
The product appearance of the oleanolic acid nanoemulsion compositions prepared in examples 1-6 is shown in fig. 1.
Test example 1: experiment of effect of oleanolic acid nanoemulsion on androgen alopecia model mice
1.1 Experimental animals
40 male C57BL/6 mice were selected, with a body weight of 16-18g and an age of 3-4 weeks. All rats are placed in an animal room with appropriate temperature and humidity for breeding, and ventilation is carried out for 1-2 times every day, and each time lasts for 1 hour. Each 12h day and night was guaranteed to alternate daily while remaining quiet and avoiding other disturbances. Ensure that the mouse has enough activity space. The mice are fed with the maintenance feed, the purified water is used as the drinking water of the rats, and the drinking water and the feed are replaced every day to keep the ventilation, sanitation and hygiene of the living environment of the animals. Lighting in day (12 +/-2) h, indoor temperature (20 +/-2) DEG C and relative humidity of 40-60%.
1.2 grouping
40 rats were randomly divided into 5 groups, group 1: blank control group 8; group 2: 8 models are selected; group 3: 8 minoxidil groups; group 4: 8 oleanolic acids; group 5: oleanolic acid + Oleuropein + baicalin group 8.
1.3 Experimental drugs
The minoxidil group used a commercially available 5% minoxidil solution; the group of oleanolic acid used the nanoemulsion prepared in example 1, and the group of oleanolic acid + oleuropein + baicalin used the nanoemulsion prepared in example 4.
1.4 Molding
All mice were injected subcutaneously in the back with testosterone propionate at a dose of 5 mg/kg/day 1 time per day for 4 weeks, except for a blank group, which was injected with an equal amount of physiological saline at the same site in the back of the mice.
1.5 administration of drugs
After 4 weeks of successful molding, the placebo group was injected subcutaneously with normal saline, and the remaining groups were continuously injected subcutaneously with testosterone propionate for 4 weeks to maintain androgen levels in the mice. The model group was continuously injected with testosterone propionate only at 5 mg/kg/day, group 3 was evenly coated with 5% minoxidil after injecting testosterone propionate for 1 hour each time, group 4 was coated with 1% oleanolic acid nanoemulsion prepared in example 1, and group 5 was coated with the oleanolic acid nanoemulsion composition prepared in example 4.
1.6 Experimental animal observations
1.6.1 general State Observation
The unhairing degree of each group of rats is observed every day, and the local skin reactions such as red swelling, edema, effusion and the like do not appear in the medicine smearing area.
1.6.2 preparation of skin tissue sections
After 8 weeks of the experiment, the dorsal depilation region of each group of mice was selected, the material was taken parallel to the spinal column and was approximately 1X 1m2, and 3 skin tissue sections of substantially the same area were taken from each mouse. Preparing a specimen according to a conventional skin histopathological process, embedding the specimen in paraffin, slicing, HE staining, observing morphological change of hair follicles of a mouse under a microscope, counting the total number of the hair follicles in a 100-field view, taking the average value of three slices, and carrying out related statistical analysis, wherein data are expressed by X +/-SD. When p is less than 0.05, the difference is significant and has statistical significance.
1.7 results of the experiment
1.7.1 section Hair follicle Observation and Hair follicle enumeration
Observing the cross section of the skin hair follicle, and after the external medicine is applied for 4 weeks, the hair of the blank control group is complete and thick, and is black and glossy; compared with the blank group, the model group has obviously increased alopecia area; the hair loss area of the minoxidil group and the mice of the group 3 and the group 4 is obviously reduced compared with that of the model group, and the figure is shown in figure 2.
TABLE 7 comparison of Hair follicle counts for each group
Group of | Total number of hair follicles |
Blank control group (group 1) | 38.75±4.12 |
Model set (set 2) | 13.31±3.42* |
Minoxidil group (group 3) | 30.38±8.32 # |
Oleanolic acid group (group 4) | 31.63±6.73 & |
Oleanolic acid + Oleuropein + baicalin group (group 5) | 34.12±8.85 #$ |
Note comparison of p with blank control group<0.05; # In comparison with the modeling group, p<0.05;&In comparison with minoxidil group, p>0.05; $ In comparison with minoxidil group, p<0.05。
As can be seen from table 7, the oleanolic acid group (group 4) had a clear therapeutic effect on androgenetic alopecia model mice, and the effect was not statistically significantly different (P > 0.05) compared to the 5% minoxidil group; the group 4, oleanolic acid, oleuropein and baicalin, has better comprehensive effects of promoting hair growth and reducing alopecia than the minoxidil group on androgenetic alopecia mice (P <0.05, table 7).
Test example 2 stability study of Oleanolic acid nanoemulsion formulations
1) Effect of centrifugal acceleration test on nanoemulsion stability
The prepared nano emulsion is centrifuged at 20000r/min, and the appearance of the nano emulsion is still clear and transparent after being observed for 15min, and the phenomenon of oil-water stratification is not generated.
2) Light stability test
The nano-emulsion is put into a glass bottle in proper amount, sealed and placed at room temperature under the condition of 5000 +/-500 lx illumination, and sampled and observed at 1d, 3d and 7d respectively. The results show that the nanoemulsion keeps clear and transparent appearance, and the phenomena of layering, emulsion breaking and the like are not seen.
3) Observation test of retained sample
The emulsion is subpackaged in glass bottles, sealed and respectively placed at 4 ℃, 25 ℃ and 40 ℃ for sample observation for 6 months, and sampled and observed at intervals of 14 days. The results show that the emulsion keeps clear and transparent appearance under the four temperature conditions, and the phenomena of layering, emulsion breaking and the like are not seen.
Test example 3: animal skin irritation study of Oleanolic acid nanoemulsion formulations
New Zealand white rabbits are more sensitive to the response of stimulating substances than humans. The skin irritation test was performed on examples 4 to 6 using 12 healthy New Zealand white rabbits, each half of which was divided into 3 groups of 4 rabbits each, each half of which was female and male. The two sides of the spine of the animal are unhaired by an electric shaver 24 hours before administration, and the area of the unhaired area is 5 multiplied by 5cm. The skin is externally applied for 2 times every day, the skin is continuously applied for 14d as a test period, the animal skin irritation test result is non-irritant according to skin irritation intensity classification of 'cosmetic hygiene Specifications' (2002), and the oleanolic acid essential oil nanoemulsion and the nanoemulsion gel have no obvious irritation to New Zealand white rabbits.
Test example 4: solubilization of essential oil with oleanolic acid
Adding appropriate amount of oleanolic acid into 5mL centrifuge tube, adding 1g of each adjuvant, respectively, performing ultrasonic treatment for 30min, maintaining the temperature at 60 deg.C, oscillating at 100r/min for balancing for 48h, centrifuging at 10000r/min for 10min, collecting supernatant, diluting the filtrate with methanol by appropriate times, performing sample HPLC, and calculating oleanolic acid content in each adjuvant.
The solubility of oleanolic acid in different solvents is shown in table 8, and it can be seen from table 8 that the solubility of essential oil oleanolic acid is much higher than that of common solvents, and the combination of essential oil and cosurfactant has better solubilization and hydrotropy effects.
Table 8: oleanolic acid solubility (mg/ml) of different solvents
Experiments have shown that the topical compositions of the present invention can be used in the preparation of products for treating and controlling the adverse effects of skin conditions including, but not limited to, androgenetic alopecia, telogen effluvium, alopecia areata, or other types of alopecia, acne, seborrheic dermatitis, folliculitis, skin aging, and other skin conditions.
The oleanolic acid nanoemulsion composition of the present invention is applied to cosmetics, and can be used for skin care, hair care, and the like.
The oleanolic acid nanoemulsion composition can be used as a dosage form for caring skin or hair by adding an excipient into the oleanolic acid nanoemulsion composition, and the oleanolic acid nanoemulsion composition is used alone as a product, or is mixed with other cosmetic or pharmaceutical raw materials to be prepared into nanoemulsion gel, ointment, cream, emulsion, spray, lotion, liniment, patch or liniment.
The oleanolic acid nanoemulsion composition of the present invention can be prepared into products including, but not limited to, hair growth lotions, hair care essences, skin care gels, shampoos, hair conditioners, mascaras, masks, creams, and lotions.
The above-described embodiments are merely preferred embodiments of the present invention, and should not be considered as limiting the scope of the invention. All equivalent changes and modifications made within the scope of the present invention shall fall within the scope of the present invention.
Claims (10)
1. A high-concentration oleanolic acid nanoemulsion composition is characterized by comprising the following components in percentage by weight:
0.01 to 8 percent of oleanolic acid, 1 to 40 percent of surfactant, 1 to 40 percent of cosurfactant, 0.2 to 20 percent of essential oil containing terpene, 0 to 2 percent of baicalin, 0 to 5 percent of oleuropein, a proper amount of additive and the balance of water.
2. The high concentration oleanolic acid nanoemulsion composition of claim 1, comprising the following components in percentage by weight:
0.5-2% of oleanolic acid, 10-30% of surfactant, 10-25% of cosurfactant, 1-10% of terpene-containing essential oil, 0.1-1% of baicalin, 0.5-2% of oleuropein, a proper amount of additive and the balance of water.
3. The high concentration oleanolic acid nanoemulsion composition of claim 1 or 2, wherein said oleanolic acid is pure or a plant extract containing oleanolic acid; the plant extract contains at least 2% of oleanolic acid, and can be selected from fructus Ligustri Lucidi extract, herba Swertiae Bimaculatae extract, and Olea europaea extract;
the surfactant is preferably a nonionic surfactant; the HLB value of the surfactant can be 8-18, preferably 10-15; the surfactant can be selected from at least one of PEG-6 caprylic/capric glyceride, PEG-8 caprylic/capric glyceride, tween 80, tween 20, polyoxyethylene 40 hydrogenated castor oil, polyoxyethylene castor oil, span 80, glyceryl monostearate, hydrogenated lecithin, steareth, polyethylene glycol stearate and polyglycerol fatty acid ester;
the cosurfactant can be at least one of diethylene glycol monoethyl ether, dipropylene glycol, 1, 3-butanediol, ethanol, 1, 2-pentanediol, 1, 2-hexanediol, propylene glycol, glycerol and polyethylene glycol; preferably diethylene glycol monoethyl ether;
the terpene-containing essential oil can be at least one selected from eucalyptus oil, tea tree essential oil, cedar essential oil, peppermint essential oil, lavender essential oil, and rosemary essential oil; the terpene comprises at least one of monoterpene, sesquiterpene and diterpene.
4. The high concentration oleanolic acid nanoemulsion composition as claimed in claim 1 or 2, wherein the terpene-containing essential oil comprises, by weight, eucalyptus oil 0.2% -10%, tea tree essential oil 0.2% -10%, cedar essential oil 0.3% -5%, peppermint essential oil 0.8% -3.2%, lavender essential oil 0.6% -2.4%, rosemary essential oil 0.5% -3.2%, preferably: eucalyptus oil 0.3-12%, tea tree essential oil 0.3-10%, cedar essential oil 0.3-5%, peppermint essential oil 0.8-3.2%, lavender essential oil 0.6-2.4%, rosemary essential oil 0.5-3.2%; more preferably: eucalyptus oil 0.5-2%, tea tree essential oil 0.5-2%, cedar essential oil 0.3-1%, peppermint essential oil 0.8-2.0%, lavender essential oil 0.5-1.2%, rosemary essential oil 0.5-1.6%.
5. The high concentration oleanolic acid nanoemulsion composition of claim 1 or 2, wherein said additive comprises at least one of a thickener, a moisturizer, a pH adjuster, a preservative, an antioxidant, a conditioner, a chelating agent, an ultraviolet absorber, a nutrient, an emollient, an antiandrogen, a hair restorer, etc.
6. The high concentration oleanolic acid nanoemulsion composition of claim 5, wherein said thickener is selected from the group consisting of carbomer, hydroxyethyl cellulose, sodium carboxymethyl cellulose, sodium alginate, polycarbophil, poloxamer, xanthan gum, aloe vera gum, guar gum, polyquaternium Q-10, acrylic acid, acrylates; carbomers are preferred; the using amount of the thickening agent is preferably 0.1-5% of the total weight of the nanoemulsion;
the humectant can be at least one selected from Astragalus polysaccharides, sodium hyaluronate, dipotassium glycyrrhizinate, glycerol, polyethylene glycol, sorbitol, maltitol, aloe gel, sodium lactate, and squalane; preferably astragalus polysaccharides and sodium hyaluronate; the usage amount of the humectant is preferably 0.5 to 5 percent of the total weight of the nano-emulsion;
the pH modifier may be selected from citric acid, malic acid, lactic acid, phosphoric acid, triethanolamine, and combinations thereof, preferably triethanolamine; the usage amount of the pH regulator is preferably 0.1-1% of the total weight of the nanoemulsion;
the preservative can be selected from p-hydroxyacetophenone, phenoxyethanol, benzoic acid, caprylhydroxamic acid, caprylyl glycol, methyl paraben, ethyl paraben, propyl paraben, butyl paraben, dimethylaminoethanol, benzalkonium chloride and benzalkonium bromide, and the usage amount of the preservative is preferably 0.1-0.6% of the total weight of the nanoemulsion;
the antioxidant is selected from one or more of sodium bisulfite, vitamin E, vitamin C, lauryl gallate, propyl gallate, phenethyl caffeate, arbutin, ferulic acid, magnesium ascorbyl phosphate, sodium ascorbyl phosphate and ascorbyl ethyl ether;
the conditioner is one or more of allantoin, dipotassium glycyrrhizinate, tocopherol acetate, baicalein, olive leaf extract, scutellaria baicalensis extract, lavender extract, chamomile extract, witch hazel extract, purslane extract, gentian root extract and rosemary extract;
the chelating agent is selected from EDTA, EDTA-2Na or EDTA-4Na;
the ultraviolet absorbent is at least one selected from baicalin derivatives, quercetin derivatives, p-aminobenzoic acid derivatives, salicylic acid derivatives, benzophenone derivatives, diphenyl acrylate, and cinnamic acid derivatives;
the nutrient is selected from at least one of lysine, cystine, arginine, collagen, biotin, chondroitin sulfate, keratan sulfate, heparin sulfate, polypeptide, vitamin A, B1, B2, B6, E, C and vitamin C derivatives;
the emollient is selected from cetostearyl alcohol, lanolin, isopropyl isostearate, vaseline, liquid paraffin, polydimethylsiloxane, dimethiconol, dimethicone, shea butter, cetyl isooctanoate, natural squalane, octyl methoxycinnamate;
the antiandrogen agent is selected from at least one of finasteride, dutasteride, epristeride, flutamide, bicalutamide, safflor yellow, equol, soy isoflavone, ligustilide, hinokiflavone, saw palmetto extract, sophora flavescens extract, salvia miltiorrhiza extract, lavender extract, genistein, turmeric extract, emblic leafflower fruit extract, nettle extract, speranskia herb extract, ganoderma lucidum extract, dittany bark extract, azelaic acid, quercetin, myricetin, magnolol, luteolin, kaempferol, rutin, tea polyphenol, curcumin, emodin, baicalein, tea tree extract, kudzu root extract, genistein, scutellaria root extract, spironolactone, cimetidine, cyproterone, hexestrol, 11-alpha-hydroxyprogesterone, diosolone, levonorgestrel, and norethindrone;
the hair restorer is at least one selected from Polygoni Multiflori radix extract, fructus Ligustri Lucidi extract, carthami flos extract, cacumen Platycladi extract, herba Rosmarini officinalis extract, ginseng radix extract, notoginseng radix extract, green tea extract, herba Centellae extract, herba Swertiae Bimaculatae extract, semen Pisi Sativi extract, ginsenoside, radix Angelicae sinensis extract, olea europaea extract, radix astragali extract, rhizoma Ligustici Chuanxiong extract, rhizoma Zingiberis recens extract, semen Sesami Niger extract, semen Cuscutae extract, ecliptae herba extract, folium Mori extract, epigallocatechin gallate, cedrol, stilbene glucoside, adenosine, caffeine and minoxidil.
7. The high concentration oleanolic acid nanoemulsion composition of claim 1 or 2, wherein said water is selected from distilled water, purified water and/or deionized water, preferably distilled water.
8. A method for preparing an oleanolic acid nanoemulsion composition as claimed in claim 1 or 2, characterized by comprising the steps of:
1) Adding the cosurfactant and the essential oil containing terpene into a container A according to the formula amount, and uniformly mixing and stirring; adding the surfactant with the formula amount, and uniformly mixing; then adding oleanolic acid with formula amount, and further adding other liposoluble components (such as baicalin) and stirring to dissolve completely;
2) Adding water with the formula amount into the container B, and further adding a proper amount of additives to obtain a water phase;
3) Slowly adding the mixture in the container A into the water phase in the container B while stirring to obtain primary emulsion;
4) Carrying out high-speed shearing emulsification on the primary emulsion prepared in the step 3), carrying out secondary emulsification by using a high-pressure homogenizing emulsification device, and fully emulsifying to obtain the oleanolic acid nanoemulsion composition.
9. The method for preparing the oleanolic acid nanoemulsion composition of claim 8, wherein in step 1), the mass ratio of the co-surfactant to the terpene-containing essential oil is 4: 1 to 1: 1; the dissolution can be carried out at the normal temperature of 25-40 ℃ by stirring until the dissolution is complete, or the solution is heated and stirred under the condition of 40-80 ℃ water bath until the dissolution is complete;
in the step 4), the secondary emulsification is carried out by using a high-pressure homogenizing and emulsifying device, the homogenizing speed is 4000-10000 rpm, the homogenizing time is 3-10 min, the high-pressure homogenizing pressure is 800-1000 bar, and the homogenization is carried out for 3-5 times; the average particle size of the liquid drops in the prepared oleanolic acid nanoemulsion composition can be 10-200 nm, and is preferably less than 100nm; the secondary emulsification can also adopt micro-jet emulsification or ultrasonic emulsification.
10. The oleanolic acid nanoemulsion composition according to claim 1 or 2, which can be used for the preparation of cosmetics; the cosmetics include, but are not limited to, hair tonic, hair growth lotion, hair conditioner essence, skin care gel, anti-aging preparation, shampoo, skin foundation, essence emulsion, lotion, toner, acne lotion, emulsion, microemulsion, shampoo, gel, perfume, hair wax, hair conditioner, hair mask, mascara, hair oil, massage oil, hair conditioner, hair-blacking agent, hair dye, hair spray, hair mousse;
the oleanolic acid nanoemulsion composition is used in a medicine or a cosmetic for improving or preventing alopecia, hair thinning, white hair, acne, seborrheic dermatitis, folliculitis, skin aging or other unhealthy skin conditions; the alopecia comprises androgenetic alopecia, telogen effluvium, alopecia areata or other types of alopecia;
the oleanolic acid nanoemulsion composition can be used for caring skin, hair and facial skin;
the oleanolic acid nanoemulsion composition can be added with an excipient to be used as a dosage form for skin or hair care, and the oleanolic acid nanoemulsion composition is used alone as a product, or is mixed with other cosmetic or pharmaceutical raw materials to be prepared into oleanolic acid nanoemulsion gel, ointment, cream, emulsion, spray, lotion, liniment, patch or liniment.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110419745.1A CN115607510B (en) | 2021-04-19 | 2021-04-19 | High-concentration oleanolic acid nanoemulsion composition and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110419745.1A CN115607510B (en) | 2021-04-19 | 2021-04-19 | High-concentration oleanolic acid nanoemulsion composition and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115607510A true CN115607510A (en) | 2023-01-17 |
CN115607510B CN115607510B (en) | 2024-03-08 |
Family
ID=84855020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110419745.1A Active CN115607510B (en) | 2021-04-19 | 2021-04-19 | High-concentration oleanolic acid nanoemulsion composition and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115607510B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116785215A (en) * | 2023-08-28 | 2023-09-22 | 吉林大学 | Ginseng extract composition nano system and preparation method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101991532A (en) * | 2009-08-14 | 2011-03-30 | 上海开拓者医药发展有限公司 | Self-microemulsion composition, microemulsion and preparation methods thereof |
-
2021
- 2021-04-19 CN CN202110419745.1A patent/CN115607510B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101991532A (en) * | 2009-08-14 | 2011-03-30 | 上海开拓者医药发展有限公司 | Self-microemulsion composition, microemulsion and preparation methods thereof |
Non-Patent Citations (2)
Title |
---|
LOVRO ŽIBERNA等: "Oleanolic Acid Alters Multiple Cell Signaling Pathways: Implication in Cancer Prevention and Therapy", 《INT J MOL SCI.》, vol. 18, no. 3, 16 March 2017 (2017-03-16), pages 643 * |
朱红柳等: "中草药治疗雄激素性秃发的实验研究进展", 《临床皮肤科杂志》, vol. 46, no. 11, pages 414 - 418 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116785215A (en) * | 2023-08-28 | 2023-09-22 | 吉林大学 | Ginseng extract composition nano system and preparation method and application thereof |
CN116785215B (en) * | 2023-08-28 | 2023-12-19 | 吉林大学 | Ginseng extract composition nano system and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN115607510B (en) | 2024-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113230172B (en) | Cosmetic or dermatological composition, preparation method and application thereof | |
CN108201513B (en) | Hair composition and hair restorer | |
EP2094286B1 (en) | Compositions and methods of inducing hair growth utilizing continus coggygria | |
US20090123564A1 (en) | Novel compositions for hair disorders and process of preparation thereof | |
KR102257342B1 (en) | Composition for antimicrobial and anti-inflammatory activities and manufacturing method thereof | |
CN114796000A (en) | Micro-emulsified composition of oleanolic acid and preparation method and application thereof | |
CN110787088A (en) | Basic composition for lip wrinkle fading and preparation method and application thereof | |
WO2001074326A1 (en) | Agents improving skin barrier function | |
CN115607510B (en) | High-concentration oleanolic acid nanoemulsion composition and preparation method thereof | |
TWI703988B (en) | Methods and compositions for enhancing hair quality using blackberry extract | |
KR20200076101A (en) | Natural hair growth agent and manufacturing method thereof | |
JP2003221315A (en) | Skin care preparation for external use to be used for hair growth | |
JP3667291B2 (en) | Topical skin preparation | |
CN110917105A (en) | Allergy-relieving cosmetic composition and preparation method thereof | |
CN110721101A (en) | Self-prepared two-component essence cream and preparation method thereof | |
CN112870127B (en) | Herbal composition rich in ginseng essence and capable of repairing sensitive skin and preparation method of herbal composition | |
JP3974003B2 (en) | Hair growth material and external preparation for skin containing the same | |
KR100983076B1 (en) | Skin cream cosmetic composition | |
KR20080011970A (en) | Compositions for prevention of hair loss or hair restoration containing extracts of pueraria plants | |
JP3504590B2 (en) | External preparation for skin | |
JPH08231352A (en) | Hair tonic | |
Narole et al. | FORMULATION AND INVITRO EVALUATION OF HERBAL SKIN WHITENING CREAM OF SWEET LIQUORICE EXTRACT AND SOLANUM LYCOPERSICUM JUICE | |
JPH11302128A (en) | Cosmetic for scalp and hair | |
JP2011063513A (en) | Anti-aging agent and external preparation for skin | |
Bais et al. | Fabtech college of Pharmacy, Sangola-413307 Corresponding author mail ID-priyankakolasepatil4@ gmail. com |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Country or region after: China Address after: 2nd Floor, No. 53 Banmei Road, Jinjiang City, Fujian Province, 362200 Applicant after: Quanzhou Daxun Biotechnology Co.,Ltd. Address before: 362200 No. 1302, A3, building 6, Huijing City, Shuanggou community, Meiling street, Jinjiang City, Quanzhou City, Fujian Province Applicant before: Quanzhou Daxun Biotechnology Co.,Ltd. Country or region before: China |
|
GR01 | Patent grant | ||
GR01 | Patent grant |